A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo - 18/04/17
Doi : 10.1016/j.jaad.2016.06.015
Stefan G. Vanderweil, MD, Shinya Amano, MD, PhD, Wei-Che Ko, MS, Jillian M. Richmond, PhD, Michelle Kelley, MSN, RN, Maryanne Makredes Senna, MD, Andrea Pearson, MD, Sandhya Chowdary, MD, Celia Hartigan, RN, MPH, Bruce Barton, PhD, John E. Harris, MD, PhD ⁎ 
Department of Medicine, Division of Dermatology, University of Massachusetts Medical School, Worcester, MA
∗Correspondence to: John E. Harris, MD, PhD, University of Massachusetts Medical School, Lazare Research Bldg, Room 225, 364 Plantation St, Worcester, MA 01605University of Massachusetts Medical SchoolLazare Research Bldg, Room 225364 Plantation StWorcesterMA01605
| Funding sources: National Institutes of Health (NIH) Clinical and Translational Sciences Award UL1TR000161 through a Pilot Project Grant from the University of Massachusetts Center for Clinical and Translational Sciences; Physician-Scientist Career Development Award from the Dermatology Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the NIH, under Award Number AR061437; and research grants from the Charles H. Hood Foundation, Vitiligo Research Foundation, and Kawaja Family Vitiligo Research Initiative. |
|
| Conflicts of interest: None declared. |
© 2016
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 76 - N° 1
P. 150 - janvier 2017 Retour au numéro
Article précédent
- Minimal improvements in the global burden of skin disease from 1990 to 2013
- Jessica Mounessa, Taylor Braunberger, Cory A. Dunnick, Robert P. Dellavalle
- Increased blood levels of NKG2D+CD4+ T cells in patients with alopecia areata
- Yong Hyun Jang, Jin Kyeong Choi, Yun Hwan Jang, Sun Young Moon, Weon Ju Lee, Seok-Jong Lee, Young-Ae Choi, Sang-Hyun Kim, Do Won Kim
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?